Prediction: This Is What Eli Lilly Stock Will Do Next

Group 1: Company Performance - Eli Lilly's stock has increased by 136% since the beginning of 2023, significantly outperforming the S&P 500 and Nasdaq indices [1][2] - The company's revenue from its diabetes medication Mounjaro reached $5.2 billion in 2023, with a projected revenue run rate of $7.2 billion for 2024 [2] - Eli Lilly's stock has gained 51% in 2024 alone, reflecting strong market momentum [5] Group 2: Market Potential - The GLP-1 market, which includes Eli Lilly's treatments, is projected to be worth $100 billion by 2030, indicating substantial growth potential [3] - The FDA has approved expanded indications for some GLP-1 treatments, suggesting that the market size could exceed current forecasts [3] - Eli Lilly's recent FDA approval for its Alzheimer's medication, donanemab, opens up another multibillion-dollar market opportunity [4] Group 3: Stock Split Consideration - A stock split could be beneficial for Eli Lilly, as high share prices may deter some investors [5] - Historical trends show that companies with significant stock gains, like Nvidia and Tesla, have opted for stock splits [5] - While speculation exists regarding a potential stock split, there is no guarantee it will occur [6] Group 4: Investment Outlook - Eli Lilly is positioned to disrupt the healthcare space, particularly in weight loss and diabetes care, with a promising long-term growth outlook [7] - The entry into the Alzheimer's market further enhances the company's growth prospects across various medical areas [7] - Eli Lilly stock is viewed as a compelling opportunity for long-term investors at this time [7]